Riskpilot← Back to searchSign inGet full accessALLERGAN AS
ASActiveOrg 937658265Karenslyst Allé 8, 0278 OsloActivities of agents involved in the wholesale of other particular products · NACE 4618Est. 19859 employees
Revenue 2020
NOK 26,6M
-2% vs 2019
EBITDA margin
8.7%
-11% vs 2019
Equity ratio
76.7%
Financial strength
Net profit 2020
NOK 1,8M
-8% vs 2019
| Revenue | NOK 26,6M | -2% |
| EBITDA | NOK 2,3M | -11% |
| Net profit | NOK 1,8M | -8% |
| Total assets | NOK 20,6M | +10% |
| Equity | NOK 15,8M | +13% |
| Employees | 9 | — |
Legal name
ALLERGAN AS
Org number
937658265
Legal form
Aksjeselskap
NACE code
4618 · Activities of agents involved in the wholesale of other particular products
Founded
27. november 1985
Share capital
NOK 100 000
Employees
9 (FTE)
VAT registered
No
Audit selected
No
Last report
2020-12-31
Financial year
January – December
Signatory rights
Styrets medlemmer hver for seg.
Address
Karenslyst Allé 8, 0278 Oslo
Phone
+4780010497
Email
liz.shea@abbvie.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|
| Revenue | 36 165 | 39 020 | 29 092 | 27 263 | 26 635 |
| Staff expenses | −14 515 | −17 548 | −13 118 | −13 105 | −12 348 |
| EBITDA | 3 302 | 4 327 | 2 609 | 2 592 | 2 319 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 3 302 | 4 327 | 2 609 | 2 592 | 2 319 |
| Net financials | 37 | 50 | 92 | −3 | 21 |
| Profit before tax | 3 338 | 4 376 | 2 701 | 2 589 | 2 340 |
| Tax | 992 | 1 146 | 655 | 640 | 548 |
| Net profit | 2 346 | 3 230 | 2 046 | 1 949 | 1 792 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|
| Total assets | 16 390 | 16 602 | 16 272 | 18 659 | 20 573 |
| Equity | 6 765 | 9 995 | 12 041 | 13 990 | 15 782 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 9 625 | 6 607 | 4 231 | 4 669 | 4 791 |
| Total debt | 9 625 | 6 607 | 4 231 | 4 669 | 4 791 |
EBITDA margin
8.7%
This company
15.8%
Market median
-45% vs market
20162020
Equity ratio
76.7%
This company
38.2%
Market median
+101% vs market
20162020
Return on equity
11.4%
This company
18.4%
Market median
+38% vs market
20162020
Net profit margin
6.7%
This company
8.1%
Market median
-17% vs market
20162020
Asset turnover
1.29×
This company
1.12×
Market median
+15% vs market
20162020
Debt / equity
0.30×
This company
0.62×
Market median
+52% vs market
20162020
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
KS Contact Person | Contact Person | 2018 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2021 | |
| Board of Directors | 2021 | |
| Chairman | 2021 | |
| Former (1) | ||
| Board of Directors | 2021 – 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ALLERGAN AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Karianne Sæther Lyche | Contact Person | 0 companies |
| Birgitta Susanne Svensson | Board of Directors | 0 companies |
| Emilie Claudine Demare | Board of Directors | 0 companies |
| Paul Roger Johnson | Chairman | 0 companies |
| Anna Lovisa Sondefors | Board of Directors | 0 companies |